Fogorvosi szemle, 2007 (100. évfolyam, 1-6. szám)
2007-10-01 / 5. szám
FOGORVOSI SZEMLE 100. évf. 5. sz. 2007. 231 diographic effects of enamel matrix derivative in the treatment of intrabony periodontal defects: a 12-month longitudinal placebo-controlled clinical trial in adult periodontitis patients. J Periodontol2005; 76: 129-133. 97.0kudaK, MomoseM, Miyazaki A, Murata M, Yokohamas, YonezawaY, Wolff LF, Yoshie H: Enamel matrix derivative in the treatment of human intrabony osseous defects. J Periodontol 2000; 71: 1821- 1828. 98. Silvestri M, Ricci G, Rasperini G, Sartori S, Cattaneo V: Comparison of treatments of intrabony defects with enamel matrix derivative, guided tissue regeneration with a nonresorbable membrane and Widman modified flap. A pilot study. J Clin Periodontol2000; 27: 603-610. 99. Sculean A, Windisch P, Chiantella GC, Donos N, Brecx M, Reich E: Treatment of intrabony defects with enamel matrix proteins and guided tissue regeneration. A prospective controlled clinical study. J Clin Periodontol 2001; 28: 397-403. 100. Zuchelli G, Bernardi F, Montebugnoli L, De Sanctis: Enamel matrix proteins and guided tissue regeneration with titanium-reinforced expanded polytetrafluoroethylene membranes in the treatment of intrabony defects: a comparative controlled clinical trial. J Periodontol 2002; 73: 3-12. 101. Silvestri M, Sartori S, Rasperini G, Ricci G, Rota C, Cattaneo V: Comparison of intarbony defects treated with enamel matrix derivative versus guided tissue regeneration with a nonresorbable membrane. J Clin Periodontol 2003; 30: 386-393. 102. Wachtel H, Schenk G, Bohm S, Weng D, Zuhr O, Hurzeler MB: Microsurgical access flap and enamel matrix derivative for the treatment of periodontal intrabony defects: a controlled clinical study. J Clin Periodontol 2003; 30: 496-504. 103. Yilmaz S, Kuru B, Altuna-Kirac E: Enamel matrix proteins in the treatment of periodontal sites with horizontal type of bone loss. J Clin Periodontol 2003; 30: 197-206. 104. Tonetti MS, Fourmousis I, Sauvan J, Cortellini P, Brägger U, Lang NP: Healing, post-operative morbidity and patient perception of outcomes following regenerative therapy of deep intrabony defects. J Clin Periodontol2004; 31: 1092-1098. 105. Sculean B, Blaes A, Arweiler N, Reich E, Donos N, Brecx M: The effect of postsurgical antibiotics on the healing of intrabony defects following treatment with enamel matrix proteins. J Periodontol 2001; 72: 190-195. 106. Sculean A, Berakdar M, Donos N, Auschill TM, Arweiler NB: The effect of postsurgical administration of a selective cyclo-oxygenase-2 inhibitor on the healing of intrabony defects following treatment with enamel matrix proteins. Clin Oral Invest 2003; 7: 108-112. 107. Parashis AO.TsiklakisK, TatakisDN: EDTAgel root conditioning: lack of effect on clinical and radiographic outcomes of intrabony defect treatment with enamel matrix derivative. J Periodontol 2006; 77: 103-110. 108. Sculean A, Berakdar M, Willershausen B, Arweiler NB, Becker J, Schwarz F: Effect of EDTA root conditioning on the healing of intrabony defects treated with an enamel matrix protein derivative. J Periodontol (in press). 109. Sculean A, Donos N, Blaes A, Lauermann M, Reich E, Brecx M: Comparison of enamel matrix proteins and bioabsorbable membranes in the treatment of intrabony periodontal defects. A splitmouth study. J Periodontol 1999; 70: 255-262. 110. Sanz M, Tonetti MS, Zabalegui I, Sicilia A, Blanco J, Rebelo H, Rasperini G, Merli M, Cortellini P, Sauvan JE: Treatment of intrabony defects with enamel matrix proteins or barrier membranes: results from a multicenter practice-based clinical trial. J Periodontol2004; 75: 726-733. 111. Francetti L, Del Fabro M, Basso M, Testőri T, Weinstein R: Enamel matrix proteins in the treatment of intra-bony defects. A prospective 24-month clinical trial. J Clin Periodontol2004; 31: 52-59. 112. Francetti L, Trombelli L, Lombardo G, Guida L, Cafiero C, Roccuzzo M, Carusi G, Del Fabro M: Evaluation of efficacy of enamel matrix derivative in the treatment of intrabony defects: a 24-month multicenter study. Int J Periodontics Restorative Dent 2005; 25: 461-473. 113. Sculean A, Donos N, Miliauskaite A, Arweiler N, Brecx M: Treatment of intrabony defects with enamel matrix proteins or bioresorbable membranes. A four year follow up splith-mouth study. J Periodontol 2001; 72: 1695-1701. 114. Sculean A, Donos N, Schwarz F, Becker J, Brecx M, Arweiler NB: Five year results following treatment of intrabony defects with enamel matrix proteins and guided tissue regeneration. J Clin Periodontol 2004; 31: 545-549. 115. Wikesjö UME, Selvig KA: Periodontal wound healing and regeneration. Periodontol 2000 1999; 19: 21-39. 116. Tonetti MS, PiniPratoG, Cortellini P: Factorsaffectingthehealing response of intrabony defects following guided tissue regeneration and access flap surgery. J Clin Periodontol 1996; 23: 548-556. 117. Minabe M, Kodama T, Kogou T, Takeuchi K, Fushimi H, Sugiyama T, Mitarai E: A comparative study of combined treatment with a collagen membrane and enamel matrix proteins for the regeneration of intraosseous defects. Int J Periodontics Restorative Dent 2002; 22: 595-605. 118. Sipos PM, Loos BG, Abbas F, Timmerman MF, van der Velden U: The combined use of enamel matrix proteins and a tetracycline-coated expanded polytetrafluoroethylene barrier membrane in the treatment of intra-osseous defects. J Clin Periodontol 2005; 32: 765- 772. 119. Sculean A, Windisch P, KeglevichT.ChiantellaGC, Gera I, Donos N: Clinical and histologic evaluation of human intrabony defects treated with an enamel matrix protein derivative combined with a bovine-derived xenograft. Int J Periodont Rest Dent 2003; 23: 47-55. 120. Sculean A, Windisch P, Keglevich T, Gera I: Clinical and histological evaluation of an enamel matrix protein derivative combined with a bioactive glass for the treatment of intrabony periodontal defects in humans. Int J Periodont Rest Dent 2005; 25: 139-147. 121. Lekovic V, Camargo PM, Weinlaender M, Nedic M, Aleksic Z, Kenney BE: A comparison between enamel matrix proteins used alone or in combination with bovine porous bone mineral in the treatment of intrabony periodontal defects in humans. J Periodontol 2000; 71: 1695-1701. 122. Velasquez-Plata D, Scheyer ET, Mellonig JT: Clinical comparison of an enamel matrix derivative used alone or in combination with a bovine-derived xenograft for the treatment of periodontal osseous defects in humans. J Periodontol 2002; 73: 433-440. 123. Zucchelli G, Amore C, Montebugnoli L, De Sanctis M: Enamel matrix proteins and bovine porous mineral in the treatment of intrabony defects: a comparative controlled clinical trial. J Periodontol 2003; 74: 1725-1735. 124. Gurinsky BS, Mills MP, Mellonig JT: Clinical evaluation of demineralized freeze-dried bone allograft and enamel matrix derivative versus enamel matrix derivative alone for the treatment of periodontal osseous defects in humans. J Periodontol 2004; 75: 1309- 1318. 125. Sculean A, Pietruska M, Schwarz F, Willershausen B, Arweiler NB, Auschill TM: Healing of human intrabony defects following regenerative periodontal therapy with an enamel matrix protein derivative alone or combined with a bioactive glass. A controlled clinical study. J Clin Periodontol 2005; 32: 111-117. 126. Sculean A, Barbé G, Chiantella GC, Arweiler NB, Berakdar M, Brecx M: Clinical evaluation of an enamel matrix protein derivative combined with a bioactive glass for the treatment of intrabony periodontal defects in humans. J Periodontol 2002; 73: 401-408. 127. Sculean A, Chiantella GC, Windisch P, Gera I, Reich E: Clinical evaluation of an enamel matrix protein derivative (Emdogain®) combined with a bovine derived xenograft (Bio-Oss®) for the treatment of intrabony periodontal defects in humans. Int J Periodont Rest Dent 2002; 22: 259-267. 128. Scheyer ET, Velasquez-Plata D, Brunsvold MA, Lasho DJ, Mellonig JT: A clinical comparison of a bovine-derived xenograft used alone and in combination with enamel matrix derivative for the treatment of periodontal osseous defects in humans. J Periodontol 2002; 73: 423-432. 129. Modica F, Del Pizzo M, Roccuzzo M, Romagnoli R: Coronally advanced flap for the treatment of buccal gingival recessions with and